SEC Form 4 · accession 0001144204-18-022020
Bionik Laboratories Corp. · BNKL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Michel Dusseux
Officer — Chief Executive Officer · Director
Period of report
Apr 20, 2018
Accepted (ET)
Apr 24, 2018 · 1:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001508381
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.0649 | Apr 20, 2018 | A | 6,000,000 | A | Apr 20, 2018 | Apr 20, 2028 | Common Stock, par value $0.001 | 6,000,000 | 6,000,000 | D |
Explanation of responses
- F1The right of the Reporting Person to exercise the option is subject to the Issuer having sufficient authorized but unissued shares of its common stock.